1.33
-0.75%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kangmei Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600518.SS. It has been listed since 19 March 2001. In the fiscal year to 31 December 2025, it reported revenue of CN¥5.25bn and net income of CN¥10.3m. At that date it held total assets of CN¥13.22bn and shareholders' equity of CN¥7.29bn.
Kangmei Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical, health care and health food products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2001-03-19. The firm's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera flower, among others. The firm is also engaged in the trading of Chinese herbal medicines, medical equipment and healthcare products related businesses. The company also engages in the provision of real estate leasing and distribution services, among others. The firm mainly conducts its businesses within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Mar 2001
- Employees
- 6,410
- Website
- kangmei.com.cn ↗
Leadership
Pay as last reported
- Mr. Zhijian LaiChairman of the Board, since 2022CN¥1.5m
- Mr. Guibo GongChief Financial Officer, Deputy General Manager, since 2020CN¥1.4m
- Mr. Yunfeng ZhouChief Compliance Officer, Deputy General Manager, Secretary of the Board, Director, since 2020CN¥1.4m
- Mr. Guoxiong OuGeneral Manager, Director, since 2021CN¥1.2m
- Mr. Qiyun ChenDeputy General ManagerCN¥1.2m
- Mr. Zezheng HeDeputy General Manager, Chief Human Resources and Administration OfficerCN¥1.1m
- Mr. Xinquan LiuDeputy General ManagerCN¥1.2m
- Mr. Zebin LiAssistant to the General ManagerCN¥1.1m
- Ms. Jinjin ZhangAssistant to the General Manager
- Mr. Weizhong HuangDirector
- Mr. Jun LiangDirector
- Mr. Huayue XiaDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 27
- Social
- 37
- Governance
- 22
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kangmei Pharmaceutical Co Ltd has several strengths that contribute to its success within the pharmaceutical industry. Firstly, the company has a strong brand presence in the market, which helps build customer trust and loyalty. Secondly, Kangmei Pharmaceutical boasts a diverse portfolio of products, ranging from over-the-counter medicines to prescription drugs, allowing them to cater to a wide range of consumer needs. Additionally, the company has established strategic partnerships with key stakeholders, including hospitals, distributors, and research institutions, enhancing their market reach and competitiveness.
Weaknesses
- In spite of its strengths, Kangmei Pharmaceutical faces certain weaknesses that could hinder its growth prospects. One key weakness is its limited international presence, primarily focusing on the domestic Chinese market. This narrow geographical reach may impact the company's potential for global expansion in an increasingly interconnected world. Furthermore, the company relies heavily on third-party suppliers for raw materials, making them susceptible to disruptions in the supply chain, resulting in potential production delays and increased costs.
Opportunities
- There are several opportunities that Kangmei Pharmaceutical can leverage to drive further growth. The growing demand for pharmaceutical products in emerging markets presents a significant opportunity for expansion. By targeting these high-growth regions and establishing a solid international presence, Kangmei Pharmaceutical can tap into new revenue streams and diversify its customer base. Additionally, advancements in technology and digital healthcare solutions open doors for the company to enhance its product offerings and engage with customers in innovative ways.
Threats
- With opportunities come threats, and Kangmei Pharmaceutical must be aware of potential challenges in the market. One notable threat is the increasing competition from both domestic and international pharmaceutical companies. This intensifying competition may put pressure on Kangmei Pharmaceutical to differentiate its products and maintain competitive pricing strategies. Additionally, the ever-changing regulatory landscape and stringent government policies in the pharmaceutical industry can pose challenges that the company must navigate effectively to ensure compliance and avoid penalties.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.